Doximity, Inc. (DOCS)
| Market Cap | 5.61B -55.6% |
| Revenue (ttm) | 655.57M +11.2% |
| Net Income | 167.05M -29.0% |
| EPS | 0.84 -27.9% |
| Shares Out | 178.25M |
| PE Ratio | 37.39 |
| Forward PE | 22.08 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 3,132,765 |
| Open | 29.75 |
| Previous Close | 29.92 |
| Day's Range | 29.62 - 31.54 |
| 52-Week Range | 17.15 - 71.37 |
| Beta | 1.22 |
| Analysts | Hold |
| Price Target | 30.44 (-3.37%) |
| Earnings Date | Nov 5, 2026 |
About DOCS
Doximity, Inc. operates a digital platform for medical professionals in the United States. Its Doximity platform includes a personalized newsfeed that presents clinical and professional content to members, which offers medical articles, clinical trials or research results in an easy-to-consume video format, professional updates and accomplishments of their peers and colleagues, clinical discussions, Op-Med articles for publication, and sponsored content from pharmaceutical manufacturers and health systems. The company also offers workflow tools... [Read more]
Financial Performance
In fiscal year 2026, Doximity's revenue was $644.86 million, an increase of 13.05% compared to the previous year's $570.40 million. Earnings were $196.05 million, a decrease of -12.16%.
Financial StatementsAnalyst Summary
According to 21 analysts, the average rating for DOCS stock is "Hold." The 12-month stock price target is $30.44, which is a decrease of -3.37% from the latest price.
News
Doximity to Release Fiscal 2027 Second Quarter Results on November 5, 2026
SAN FRANCISCO--(BUSINESS WIRE)--Doximity, Inc. (NYSE:DOCS), the leading digital platform for U.S. medical professionals, today announced it will report financial results for its fiscal second quarter ...
DOCS Stockholders Have Rights - If you Lost Money Investing in Doximity, Inc. Contact Robbins LLP for Information About Recovering Your Losses
SAN DIEGO, Oct. 14, 2026 /PRNewswire/ -- Shareholder rights law firm Robbins LLP reminds investors that a class action was filed on behalf of persons and entities who purchased or otherwise acquired D...
Doximity extends 13-year partnership with U.S. News & World Report
Doximity (DOCS) announced it has extended its 13-year partnership with U.S. News & World Report.
Doximity and U.S. News & World Report Extend Partnership to Connect Patients with Hospitals and Doctors
SAN FRANCISCO & WASHINGTON--(BUSINESS WIRE)--Doximity (NYSE: DOCS), the leading digital platform for U.S. medical professionals, today announced it has extended its 13-year partnership with U.S. News ...
Kaplan Fox Encourages Doximity, Inc. (DOCS) Investors to Contact the Firm Before the Deadline on November 16, 2026 for a Leadership Role
New York, New York--(Newsfile Corp. - October 8, 2026) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Doximity, Inc. ("Doximity" or the "Company") (NYSE: DO...
Kaplan Fox Advises Doximity, Inc. (DOCS) Investors to Act Before the Lead Plaintiff Deadline on November 16, 2026
New York, New York--(Newsfile Corp. - October 6, 2026) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Doximity, Inc. ("Doximity" or the "Company") (NYSE: DO...
Doximity price target lowered to $35 from $40 at Evercore ISI
Evercore ISI analyst Elizabeth Anderson lowered the firm’s price target on Doximity (DOCS) to $35 from $40 and keeps an In Line rating on the shares.
Robbins LLP is Investigating Allegations that Doximity, Inc. Failed to Disclose to Investors it Was Losing Market Share to its Competitors With More Favorable Pricing and Engagement Models
San Diego, California--(Newsfile Corp. - September 28, 2026) - Shareholder rights law firm Robbins LLP reminds investors that a class action was filed on behalf of persons and entities who purchased o...
Kaplan Fox Reminds Doximity, Inc. (DOCS) Investors with Significant Losses to Seek a Leadership Role Before Deadline on November 16, 2026
New York, New York--(Newsfile Corp. - September 24, 2026) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Doximity, Inc. ("Doximity" or the "Company") (NYSE:...
Doximity Named Leading Clinical AI Benchmark in Fireworks' Cross-Industry Index
SAN FRANCISCO--(BUSINESS WIRE)--Doximity, Inc. (NYSE: DOCS), the leading digital platform for U.S. medical professionals, today announced that it has been named a founding partner in the launch of a n...
Grabar Law Office Investigates Claims on Behalf of Long-Term Shareholders of Doximity, Inc. (DOCS)
Philadelphia, Pennsylvania--(Newsfile Corp. - September 18, 2026) - Grabar Law Office is investigating potential claims on behalf of long-term shareholders of Doximity, Inc. (NYSE: DOCS) concerning wh...
DOXIMITY, INC. (DOCS) INVESTOR ALERT Investors With Large Losses in Doximity, Inc. Should Contact Bernstein Liebhard LLP To Discuss Their Rights
NEW YORK, Sept. 17, 2026 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the “Class”) who purchased or acqui...
Doximity downgraded to Hold from Buy at Freedom Capital
Freedom Capital downgraded Doximity (DOCS) to Hold from Buy with a price target of $27, up from $24. the company cut its fiscal 2027 EBITDA outlook to reflect another step-up…
Doximity Transcript: AGM 2026
The meeting covered director elections, auditor ratification, and executive compensation approval. All proposals passed, with directors elected through 2029 and Deloitte confirmed as auditor for fiscal 2027.
Overworked Doctors Bet on AI to Boost Their Pay
SAN FRANCISCO--(BUSINESS WIRE)--Doximity, Inc. (NYSE: DOCS), the leading digital platform for U.S. medical professionals, today announced new data indicating that physicians are finding an unexpected ...
Doximity price target raised to $24 from $19 at Truist
Truist analyst Jailendra Singh raised the firm’s price target on Doximity (DOCS) to $24 from $19 and keeps a Hold rating on the shares. The firm is updating its model…
Doximity downgraded to Underweight from Equal Weight at Wells Fargo
Wells Fargo downgraded Doximity (DOCS) to Underweight from Equal Weight with an unchanged price target of $18. The shares are trading at “compounder multiples” while the company is posting “market-lev...
Doximity stock is reversing post-earnings rally: why that shouldn't surprise you
Doximity (DOCS) stock as much as doubled on Friday morning after the digital platform for health care professionals posted a solid Q1 sales beat and issued seemingly impressive full-year guidance. Sti...
Here's Why Doximity Stock Is Flying Today
Shares of Doximity are rocking higher Friday. The reason?
Doximity's stock skyrockets 50% on medical AI excitement. Can the rally last?
While one analyst thinks Doximity has a compelling AI opportunity, another worries that the company could cannibalize its core business of medical networking.
Why Did Doximity (DOCS) Stock Rocket Despite Mixed Q1 Earnings?
Doximity stock saw strong gains on Friday, even after the company posted EPS below Wall Street’s estimates.
Doximity price target raised to $41 from $27 at Needham
Needham analyst Scott Berg raised the firm’s price target on Doximity (DOCS) to $41 from $27 and keeps a Buy rating on the shares. The firm views the company’s Q1…
Doximity price target raised to $38 from $23 at Raymond James
Raymond James raised the firm’s price target on Doximity (DOCS) to $38 from $23 and keeps an Outperform rating on the shares. Doximity delivered a stabilizing Q1 with reaccelerating growth,…